CPRX
HealthcareCatalyst Pharmaceuticals, Inc. · Biotechnology · $4B
What is Catalyst Pharmaceuticals, Inc.?
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuromuscular and neurological diseases. Based in Coral Gables, Florida, the company has built a specialized portfolio around conditions that have historically lacked effective treatment options.
Catalyst generates revenue by developing and commercializing approved therapies for rare, debilitating conditions in the United States. Its primary commercial products treat Lambert-Eaton myasthenic syndrome in both adult and pediatric patients. Beyond its current commercial portfolio, the company pursues pipeline expansion through license agreements and collaborations — including partnerships with BioMarin Pharmaceutical and Endo Ventures — targeting additional rare neuromuscular indications where unmet medical need remains high.
Catalyst Pharmaceuticals was founded in 2002 and is headquartered in Coral Gables, Florida.
- Firdapse (amifampridine phosphate) for adult LEMS patients
- Ruzurgi for pediatric LEMS treatment
- Pipeline programs targeting MuSK antibody positive myasthenia gravis
- Spinal muscular atrophy type 3 development program
- Generic Sabril tablet collaboration with Endo Ventures
Is CPRX a Good Stock to Buy?
UQS Score rates CPRX as Very Good overall.
The Quality and Risk pillars both register as Strong, reflecting a business model that has demonstrated financial discipline and a relatively contained risk profile compared to many development-stage peers in the rare-disease space. The Growth pillar scores as Good, supported by a commercial product base with room to expand across additional indications. Valuation is rated Attractive, suggesting the market may not yet be fully pricing in the company's fundamentals.
The Moat pillar is rated Neutral, which points to ongoing questions about long-term competitive differentiation as the rare-disease landscape grows more crowded.
Sign up to see the exact pillar breakdown and the complete financial metrics behind the CPRX UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CPRX pay dividends?
No — Catalyst Pharmaceuticals, Inc. does not currently pay a dividend.
Catalyst Pharmaceuticals does not currently pay a dividend. For a commercial-stage rare-disease company, this is typical — capital is generally directed toward pipeline development, regulatory pursuits, and potential business development activity rather than shareholder distributions. Investors in CPRX are primarily positioned for growth rather than income.
When does CPRX report earnings?
Catalyst Pharmaceuticals reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's commercial revenue base has grown alongside increasing adoption of its approved therapies. Quarterly results tend to reflect trends in patient uptake, operating expense management, and any pipeline-related milestones. Results can vary based on the timing of collaboration revenues and development spending.
For the most recent quarter's results and guidance, visit Catalyst Pharmaceuticals' investor relations page directly.
CPRX Price History
+363.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Catalyst Pharmaceuticals, Inc.?
Based on Catalyst Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CPRX Long-term Outlook
The fundamental outlook for CPRX is shaped by a Good Growth profile paired with Strong Risk characteristics — a combination that suggests measured, sustainable expansion rather than high-volatility upside. The Attractive Valuation label adds further interest for investors evaluating entry points. Key to the trajectory will be execution on pipeline indications and the durability of its commercial franchise in LEMS.
Growth drivers
- Expansion into additional rare neuromuscular indications beyond LEMS
- Continued patient uptake growth for approved commercial therapies
- Collaboration and licensing agreements that broaden the pipeline without proportional cost increases
Key risks
- Neutral Moat rating signals potential vulnerability to competitive entrants in rare-disease markets
- Pipeline programs carry inherent clinical and regulatory risk
- Concentration in a narrow therapeutic area limits diversification if lead products face headwinds
CPRX vs Peers
Catalyst Pharmaceuticals operates in a rare-disease biotech space alongside several companies pursuing distinct therapeutic strategies.
Denali focuses on neurodegenerative diseases using a transport vehicle platform, targeting a broader neurological disease scope than Catalyst's rare neuromuscular niche.
Beam pursues base-editing gene therapies, representing a technology-platform approach that differs fundamentally from Catalyst's small-molecule commercial model.
Kiniksa targets rare inflammatory and autoimmune conditions, sharing the rare-disease commercial focus but operating in a different disease category than Catalyst.
Frequently Asked Questions
What does Catalyst Pharmaceuticals do?
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and sells therapies for rare neuromuscular and neurological diseases. Its approved products treat Lambert-Eaton myasthenic syndrome in adult and pediatric patients. The company also pursues pipeline programs targeting additional rare conditions through internal development and external collaborations.
Does CPRX pay dividends?
CPRX does not currently pay a dividend. The company reinvests its resources into pipeline development and commercial expansion, which is common for commercial-stage rare-disease biotechs. Investors seeking income from dividends should factor this into their assessment.
When does CPRX report earnings?
Catalyst Pharmaceuticals reports on a quarterly cadence, as is standard for US-listed companies. The exact dates for upcoming quarters are not covered by our data source. Check the company's investor relations page for the current earnings calendar.
Is CPRX a good stock to buy?
UQS Score rates CPRX as Very Good, with Strong marks in Quality and Risk and a Good Growth profile. The Valuation pillar is rated Attractive. The Moat pillar is Neutral, which is worth monitoring. The full pillar breakdown is available to Pro members on UQS Score.
Is CPRX overvalued?
The UQS Valuation pillar for CPRX is rated Attractive, suggesting the stock may be reasonably priced relative to its fundamentals when compared to sector peers. Valuation is one of five pillars in the UQS composite — see the full analysis for context on how each pillar contributes.
How does CPRX compare to its competitors?
Catalyst Pharmaceuticals occupies a focused commercial niche in rare neuromuscular disease, differentiating it from peers like Denali Therapeutics, which targets neurodegeneration broadly, and Beam Therapeutics, which uses gene-editing platforms. Kiniksa Pharmaceuticals shares the rare-disease commercial model but operates in different disease areas.
What is CPRX's market cap bracket?
CPRX is classified as a mid-cap stock. This places it in a range that typically offers more established commercial operations than small- or micro-cap biotechs, while still carrying meaningful growth potential relative to large-cap pharmaceutical companies.
Who founded Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals was founded in 2002 and was formerly known as Catalyst Pharmaceutical Partners, Inc. before adopting its current name in May 2015. Founding details are widely available through the company's public filings and investor relations materials.
Is CPRX a long-term quality stock?
As a long-term quality indicator, CPRX scores well — the UQS Quality and Risk pillars are both rated Strong, which suggests financial discipline and a relatively stable operating profile. Long-term durability will depend on pipeline execution and whether the Neutral Moat rating strengthens over time. Pro members can view the complete analysis.
What is the main competitive advantage of Catalyst Pharmaceuticals?
Catalyst's primary advantage lies in its established commercial presence in a narrow rare-disease category with limited competition. Approved therapies for LEMS, combined with an active pipeline targeting adjacent indications, give the company a focused commercial and regulatory track record that is difficult for early-stage entrants to replicate quickly.
What sector does CPRX belong to?
CPRX belongs to the Healthcare sector, specifically within the biopharmaceutical industry. It focuses on the rare and orphan disease segment, which often carries distinct regulatory pathways and pricing dynamics compared to broader pharmaceutical markets. You can explore more [Healthcare sector stocks](/sector/healthcare) on UQS Score.
Is CPRX a growth stock or value stock?
Based on the UQS pillar profile, CPRX shows characteristics of both. The Growth pillar is rated Good and the Valuation pillar is rated Attractive, suggesting a company with meaningful growth potential that is not obviously overpriced — a profile that may appeal to investors seeking quality at a reasonable valuation.
Unlock Full CPRX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access complete financial metrics and trend data
- ✓Compare CPRX against rare-disease peers side by side
- ✓See the full risk and valuation breakdown in detail
- ✓Get alerts when CPRX pillar ratings change
- ✓Explore curated screens for quality rare-disease stocks
Pro Analysis
CPRX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 76.0 | 91.1 | 42.0 | 78.8 | 100.0 | 79.8 | -0.1 |
| May 12, 2026 | 76.1 | 91.1 | 42.0 | 78.8 | 100.0 | 80.1 | +2.7 |
| May 11, 2026 | 73.4 | 91.1 | 42.0 | 78.8 | 82.4 | 80.1 | +0.7 |
| May 10, 2026 | 72.7 | 89.4 | 42.0 | 78.8 | 82.4 | 78.6 | +0.5 |
| May 8, 2026 | 72.2 | 89.4 | 42.0 | 76.3 | 82.4 | 78.0 | -1.1 |
| May 7, 2026 | 73.3 | 91.4 | 42.0 | 76.3 | 82.4 | 82.6 | -0.7 |
| May 4, 2026 | 74.0 | 92.7 | 42.0 | 76.3 | 82.4 | 84.9 | +0.2 |
| May 3, 2026 | 73.8 | 92.7 | 42.0 | 75.4 | 82.4 | 84.7 | -0.2 |
| May 1, 2026 | 74.0 | 92.7 | 42.0 | 75.4 | 82.4 | 86.2 | +0.1 |
| Apr 26, 2026 | 73.9 | 92.7 | 42.0 | 75.4 | 82.4 | 85.0 | -0.2 |
CPRX — Pillar Breakdown
Quality
— 91.1/100 (25%)Catalyst Pharmaceuticals, Inc. demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 78.8/100 (20%)Catalyst Pharmaceuticals, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 100.0/100 (15%)Catalyst Pharmaceuticals, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 80.8/100 (15%)Catalyst Pharmaceuticals, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 42/100 (25%)Catalyst Pharmaceuticals, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CPRX.
Score Composition
Financial Data
More Stock Analysis
How is the CPRX UQS Score Calculated?
The UQS (Unified Quality Score) for Catalyst Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Catalyst Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Catalyst Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.